Table 3.
Description of normal, premalignant, and malignant breast tissues utilized for MSP analysis along with methylation status of RASSF1A and SFRP1 in each tissue
| Sample | Description | RASSF1A | SFRP1 |
|---|---|---|---|
| N1 | Normal reduction mammoplasty tissue | U | U |
| N2 | Normal reduction mammoplasty tissue | U | U |
| N3 | Normal reduction mammoplasty tissue | M | M |
| N4 | Normal reduction mammoplasty tissue | U | U |
| N5 | Normal reduction mammoplasty tissue | U | U |
| N6 | Normal reduction mammoplasty tissue | U | U |
| N7 | Normal reduction mammoplasty tissue | U | U |
|
Total Normal Methylated |
1/7 | 1/7 | |
| H1 | Lobular hyperplasia (85% of mammary cells), blunt duct hyperplasia (15% of mammary cells) | U | U |
| H2 | Normal (80%), intraductal hyperplasia (10%), cystic hyperplasia (10%) | U | U |
|
Total Hyperplasia Methylated |
0/2 | 0/2 | |
| H3 | Focal atypical terminal duct hyperplasia (single focus); fibrocystic disease | M | M |
|
Total ADH Methylated |
1/1 | 1/1 | |
| D1 | CCL, DCIS | M | M |
| D2 | DCIS | M | M |
| D3 | DCIS, cysts, normal breast tissue | M | M |
| D4 | DCIS and normal tissue | U | M |
| D5 | Extensive comedo DCIS, calcifications | M | M |
| D6 | Extensive DCIS | M | M |
| D7 | Extensive DCIS and normal tissue | M | M |
| D8 | DCIS, calcifications | U | M |
| D9 | Extensive DCIS | M | M |
| D10 | DCIS with calcifications | M | M |
| D11 | Extensive comedo DCIS | M | M |
|
Total DCIS Methylated |
9/11 | 11/11 | |
| C1 | IDC, grade 2, node-, ER+ | M | M |
| C2 | IDC, grade 3, node+, ER- | M | M |
| C3 | IDC, grade 3, node+, ER- | U | M |
| C4 | IDC, grade 3, node-, ER- | M | M |
| C5 | IDC, grade 3, node+, ER+ | M | M |
| C6 | IDC, grade 1, node+, ER+ | M | M |
| C7 | IDC, grade 3, node+, ER- | M | M |
| C8 | IDC, DCIS, CCL, normal breast | M | M |
| C9 | IDC, DCIS | M | M |
| C10 | IDC, DCIS, normal breast | U | M |
| C11 | IDC and extensive DCIS | M | M |
| C12 | IDC and extensive comedo DCIS with calcifications | M | M |
|
Total IDC Methylated |
10/12 | 12/12 |
ADH = atypical ductal hyperplasia; CCL = columnar cell lesion; DCIS = ductal carcinoma in situ; IDC = invasive ductal carcinoma; ER = estrogen receptor; U = unmethylated; M = methylated. For SFRP1, methylation status of the CpG island located in exon 1 is shown.